RE:RE:RE:RE:Pharma companies should be lining up to partner with usManagement has been telling us for well over a year that Phase 1 funding for PMN310 is contingent on aducanumab approval, or at least that the delays in aducanumab approval were delaying investment in PMN310.
I would be shocked if they do not have a plan for capitalizing on the news today, given that they have been leading the cheers for Biogen through multiple PRs and commentaries. PMN should be the least surprised about this news.
They will certainly put out a PR, given that they have put out PRs on every aducanumab milestone to date.
And if something big is going to happen, they are not going to jeopardize it by leaking it before, even to longtime loyal shareholders.
Managing our expectations is probably a mentally healthy and perhaps wise approach, but I am all in on this one and have high high hopes for a living.
Glta